Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT04203511
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 2
- Registration Number
- NCT04189952
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC
- Conditions
- Interventions
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT04189094
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT04177004
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT04154189
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 15
- Registration Number
- NCT04139304
- Locations
- 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2021-07-16
- Target Recruit Count
- 120
- Registration Number
- NCT04129710
- Locations
- 🇨🇳
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China/Zhejiang Province, China
Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04116359
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
- Conditions
- Interventions
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 55
- Registration Number
- NCT04101357
- Locations
- 🇩🇪
University Medical Center Hamburg-Eppendorf - (Recruiting only for part 1B and part 2), Hamburg, Germany
🇩🇪Universitaetsklinikum Koeln - (Recruiting only for part 1B and part 2), Koeln, Germany
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 660
- Registration Number
- NCT04092283
- Locations
- 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
🇺🇸Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.